ESLA - NASDAQ
Estrella Immunopharma, Inc.
$1.17
+0.41%Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
At a Glance
Live SnapshotEstrella Immunopharma, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Estrella Immunopharma, Inc. Cash Flow Statement
ESLA • NASDAQ
| Estrella Immunopharma, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Jun 2024 | Dec 2022 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||
-13.1M | -8.8M | -7.3M | -996.1K | -1.7M | -733.7K | |
0.0 | 0.0 | 0.0 | 29.5K | 0.0 | 0.0 | |
0.0 | 0.0 | 1.2M | 0.0 | 130K | 62.9K | |
657.2K | 509.3K | 0.0 | -654.1K | -1.4K | 0.0 | |
(0.0) | (1.6K) | (1.6K) | (0.0) | (0.0) | (0.0) | |
10.6M | 775.7K | -10M | 576.9K | 113.4K | 0.0 | |
-1.8M | -7.6M | -16.1M | -1M | -1.4M | -670.8K | |
INVESTING ACTIVITIES | ||||||
(0.0) | (3.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | -45.2M | (0.0) | |
0.0 | 0.0 | 0.0 | 36.2M | 0.0 | 0.0 | |
0.0 | 0.0 | 5M | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (5M) | (36.2M) | -45.2M | (0.0) | |
FINANCING ACTIVITIES | ||||||
2.4M | -489.4K | -354.4K | -36.1M | 0.0 | 0.0 | |
0.0 | -10M | 0.0 | 498.6K | 0.0 | 0.0 | |
-29.5K | -568.9K | -354.4K | -36.1M | -25K | (0.0) | |
-117.5K | 9.6M | 4.1M | 50K | 530.4K | 670.8K | |
2.3M | -489.4K | 12.8M | -35.6M | 5.5M | 670.8K | |
CASH FLOW SUMMARY | ||||||
0.0 | 0.0 | 0.0 | 0.0 | 45.2M | 0.0 | |
467.4K | -8.1M | 1.7M | -438.1K | 4.1M | 0.0 | |
916.9K | 9M | 2.5M | 478.9K | 0.0 | 0.0 | |
1.4M | 916.9K | 4.2M | 40.8K | 4.1M | 0.0 | |
-1.8M | -7.6M | -16.1M | -1M | -1.4M | -670.8K |
SEC Filings
ESLA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-K/A 10-K/A 2025 FY (Amended) FY | April 30, 2026 | December 31, 2025 | 2025 | |
10-K 10-K 2025 FY FY | March 18, 2026 | December 31, 2025 | 2025 | |
S-1/A S-1/A (Amended) N/A | January 22, 2026 | January 22, 2026 | ||
S-1/A S-1/A (Amended) N/A | January 16, 2026 | January 16, 2026 | ||
8-K 8-K 2026 N/A | January 13, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 06, 2026 | January 05, 2026 | 2026 | |
S-1 S-1 N/A | December 22, 2025 | December 22, 2025 | ||
8-K 8-K 2025 N/A | December 04, 2025 | December 04, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 03, 2025 | 2025 |
Related Guides
Continue your ESLA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.